Literature DB >> 28143725

Methylation at 3'LCR of HPV16 can be affected by patient age and disruption of E1 or E2 genes.

Sérgio Menezes Amaro Filho1, Neilane Bertoni2, Ayslan Castro Brant3, João Paulo Castello Branco Vidal1, Shayany Pinto Felix1, Silvia Maria Baeta Cavalcanti4, Fernanda N Carestiato4, Luís Felipe Leite Martins2, Liz Maria de Almeida2, Miguel Angelo Martins Moreira5.   

Abstract

CpG methylation at early promoter of HPV16 DNA, in the 3' end of the Long Control Region (3'LCR), has been associated to the presence of episomal forms of viral genome and, consequently, intact E1 and E2 ORFs. The DNA methylation would block the access of E2 viral protein to the E2 binding sites at early-promoter. However, is still unclear if methylation at 3'LCR of HPV16 DNA can also vary depending of other tumor characteristics in addition to viral DNA physical state. In this study, we evaluate whether the methylation level at the five CpG located at 3'LCR of HPV16 is associated to patient age and E1 and/or E2 ORFs integrity. DNA pyrosequencing was used to measure the methylation level in 69 invasive cervical cancer samples obtained from biopsies of patients attended at Brazilian National Institute of Cancer (INCA). PCR amplifications were performed to assess disruption status of E1 and E2 genes of HPV16. The methylation average per sample ranged widely, from <1 to 88.00%. Presence of intact E1/E2 genes and patient age were positively associated with average methylation in both bivariate analyses (p=0.003 and p=0.006, respectively), and multivariate analysis (p=0.002 and p=0.021, respectively), adjusted for tumor type (squamous cell carcinomas or adenocarcinomas) and HPV16 lineage. These findings showed that presence of intact E1/E2 open reading frames was associated with high levels of DNA methylation, and older patients showed higher levels of methylation than younger ones independently of viral genome disruption.
Copyright © 2017 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Episomal HPV genome; HPV integration; HPV16; Human papillomavirus; Invasive cervical cancer; Methylation

Mesh:

Substances:

Year:  2017        PMID: 28143725     DOI: 10.1016/j.virusres.2017.01.022

Source DB:  PubMed          Journal:  Virus Res        ISSN: 0168-1702            Impact factor:   3.303


  5 in total

1.  Human Papillomavirus Type 16 E1 Mutations Associated with Cervical Cancer in a Han Chinese Population.

Authors:  Yueting Yao; Zhiling Yan; Shuying Dai; Chuanyin Li; Longyu Yang; Shuyuan Liu; Xinwen Zhang; Li Shi; Yufeng Yao
Journal:  Int J Med Sci       Date:  2019-06-24       Impact factor: 3.738

2.  Analysis of genetic variation in human papillomavirus type 16 E1 and E2 in women with cervical infection in Xinjiang, China.

Authors:  Luyue Wang; Fang Wang; Shaowei Fu; Chunhe Zhang; Xiangyi Zhe; Hongtao Li; Dongmei Li; Renfu Shao; Zemin Pan
Journal:  BMC Med Genomics       Date:  2021-11-12       Impact factor: 3.063

3.  The First Human Vulvar Intraepithelial Neoplasia Cell Line with Naturally Infected Episomal HPV18 Genome.

Authors:  Ming Wu; Xiu Zhang; Yiyi Kang; Yaqi Zhu; Zhaoyu Su; Jun Liu; Wei Zhang; Hong Chen; Hui Li
Journal:  Viruses       Date:  2022-09-16       Impact factor: 5.818

4.  HPV DNA methylation at the early promoter and E1/E2 integrity: A comparison between HPV16, HPV18 and HPV45 in cervical cancer.

Authors:  Sérgio Menezes Amaro-Filho; Cláudia Bessa Pereira Chaves; Shayany Pinto Felix; Diogo Lisbôa Basto; Liz Maria de Almeida; Miguel Angelo Martins Moreira
Journal:  Papillomavirus Res       Date:  2018-04-09

Review 5.  The role of HPV-induced epigenetic changes in cervical carcinogenesis (Review).

Authors:  Martha Laysla Ramos Da Silva; Beatriz Helena Dantas Rodrigues De Albuquerque; Thales Araújo De Medeiros Fernandes Allyrio; Valéria Duarte De Almeida; Ricardo Ney De Oliveira Cobucci; Fabiana Lima Bezerra; Vania Sousa Andrade; Daniel Carlos Ferreira Lanza; Jenner Christian Veríssimo De Azevedo; Josélio Maria Galvão De Araújo; José Veríssimo Fernandes
Journal:  Biomed Rep       Date:  2021-05-20
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.